Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

No provisions in USMCA to change U.S. pharmaceutical patent laws: Lighthizer

FILE PHOTO: U.S. Trade Representative Robert Lighthizer discusses the United States-Mexico-Canada Agreement (USMCA) as U.S. President Donald Trump and U.S. Treasury Secretary Steven Mnuchin look on during a news conference in the Rose Garden of the White House in Washington, U.S., October 1, 2018. REUTERS/Kevin Lamarque/File Photo

(Reuters) - The United States-Mexico-Canada Agreement has no provisions that would force changes to U.S. laws with respect to pharmaceutical companies, U.S. Trade Representative Robert Lighthizer said on Tuesday.

"To the extent that a member (of Congress) thinks anything in here will stop you from changing laws, then we have to correct that," Lighthizer said at a hearing of the Senate Finance Committee.

(Reporting by Chris Prentice; Editing by Susan Thomas)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.